NCT06311435 is a NA clinical trial of RNA Biomarker Blood Test in Long COVID, sponsored by MaxWell Clinic, PLC.

Who is sponsoring NCT06311435?

NCT06311435 is sponsored by MaxWell Clinic, PLC.

What drugs are being tested in NCT06311435?

Interventions in NCT06311435: RNA Biomarker Blood Test.

What condition does NCT06311435 study?

NCT06311435 studies Long COVID.

Is NCT06311435 still recruiting?

NCT06311435 is currently recruiting now. Last updated 18 October 2024.

Last reviewed 2024-10-18 · How we verify

NCT06311435

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Recruiting now NA Last updated 18 October 2024

What this trial tests

NA trial testing RNA Biomarker Blood Test in Long COVID in 224 participants. Currently enrolling.

Timeline

15 March 2024

Primary endpoint
15 March 2026

15 March 2026

Quick facts

Lead sponsor	MaxWell Clinic, PLC
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	224
Start date	15 March 2024
Primary completion	15 March 2026
Estimated completion	15 March 2026
Sites	3 locations across United States

Drugs / interventions tested

RNA Biomarker Blood Test

Conditions studied

Long COVID — all drugs for Long COVID →

Sponsor

MaxWell Clinic, PLC

Who can join

18 and older, any sex, with Long COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Long COVID

Currently open trials in the same condition.

NCT05931497 — Sauna for Long Covid · NA · recruiting
NCT06452095 — Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy fo · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
NCT07435805 — Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation · recruiting
NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting

Other MaxWell Clinic, PLC trials

Trials by the same sponsor.

NCT06079827 — Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06311435 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MaxWell Clinic, PLC
Last refreshed: 18 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06311435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing